B O O K - American College of Rheumatology

More documents

Recommendations

Info

INVITED SPEAKER /MODERATOR INDEX 312 Silvers, J. B, PhD CORC Forum: Health Care Reform – Where Are We Heading?. . . . . . . . . . . . . . . . . .101 Disclosure: Nothing to Disclose Simkin, Peter A, MD Crystal: Management of Gout . . . . . . . . 56 Disclosure: Nothing to Disclose Simms, Robert W, MD Systemic Sclerosis: New Therapeutic Approaches . . . . . . . . . . . . . . . . . .122 Disclosure: Nothing to Disclose Slusher, Barbara A, PA-C, MSW Networking at Noon . . . . . . . . . . . . . 64 From Managed Care to Medicare: Understanding Reimbursement . . . . . . . 75 Disclosure: Nothing to Disclose Smith, Benjamin J, PA-C Rheumatic Disease Update: Sjögren’s Syndrome . . . . . . . . . . . . . . . . . . . 58 Disclosure: Amgen, 5; NicOx, 5; Pfizer, 5 ARHP Networking Forum . . . . . . . . . . . 30 Disclosure: Amgen, 5; NicOx, 5; Pfizer, 5 Smolen, Josef S, MD Remission in Rheumatoid Arthritis. . . . . .135 Disclosure: Abbott, Astra-Zeneca, BMS, Centocor, Novo, Roche, Sanofi-Aventis, Schering- Plough, UCB, Wyeth, 5; Abbott, BMS, Centocor, Roche, Schering-Plough, UCB, Wyeth, 9; Abbott, BMS, Roche, Schering-Plough, UCB, Wyeth, 2 Rheumatoid Arthritis Treatment 2010: Traditional DMARDs, Biologic DMARDs and Newer Treatment Strategies . . . . . . . . 114 Disclosure: Abbott, Astra-Zeneca, BMS, Centocor, Novo, Roche, Sanofi-Aventis, Schering- Plough, UCB, Wyeth, 5; Abbott, BMS, Centocor, Roche, Schering-Plough, UCB, Wyeth, 9; Abbott, BMS, Roche, Schering-Plough, UCB, Wyeth, 2 Solomon, Daniel H, MD, MPH Session II: Applications to Musculoskeletal Medicine . . . . . . . . . . . . . . . . . . . . 19 Disclosure: abbott, amgen, 2 Rheumatoid Arthritis: Safety of Novel Therapies. . . . . . . . . . . . . . . . . . . . 65 Disclosure: abbott, amgen, 2 Somers, Emily C, PhD, ScM Top 10 in ‘10: Top 10 Public Health Advances in the First 10 Years of the Centers for Disease Control and Prevention Arthritis Program. .147 Disclosure: Nothing to Disclose Specks, Ulrich, MD Clinicopathologic Conference . . . . . . . . 55 Disclosure: Nothing to Disclose Treatment of Wegener’s Granulomatosis/ Microscopic Polyangiitis: Understanding and Applying the Data from Recent Clinical Trials . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 Disclosure: Nothing to Disclose Spiera, Robert, MD Giant Cell Arteritis - Diagnosis and Therapy. 69 Disclosure: Nothing to Disclose Treatment of Wegener’s Granulomatosis/ Microscopic Polyangiitis: Understanding and Applying the Data from Recent Clinical Trials . . . . . . . . . . . . . . . . . . . . . . . . . 48 Disclosure: Nothing to Disclose 2010 Program Book Srivastava, Sunil Kumar, MD Inflammatory Eye Disease/Uveitis . . . . . . 83 Disclosure: Bausch and Lomb, 5 St.Clair, E William, MD Session VI: Role of B cells in Autoimmunity: Lessons from Clinical Trials . . . . . . . . . . 23 Disclosure: Genentech, 2 ACR Leadership Town Hall Meeting . . . . .106 Disclosure: Genentech, 2 REF Edmond L. Dubois, MD, Memorial Lectureship . . . . . . . . . . . . . . . . . . 53 Disclosure: Genentech, 2 REF Paul Klemperer, MD, Memorial Lectureship: Systemic Sclerosis: Genetic? Autoimmune? One Disease? . . . . . . . . . . . . . . . . . . . . 98 Disclosure: Genentech, 2 Starz, Terence W, MD Understanding Functional Activity in Rheumatoid Arthritis: What We Know and What We Don’t Know . . . . . . . . . . . . . . . . 86 Disclosure: Pfizer, 5 Steen, Virginia D, MD Mixed Connective Tissue Disease is Not Really that Mixed . . . . . . . . . . . . . . . . . . . 23 Disclosure: Nothing to Disclose Sterrett, Ashley G, MD Teaching and Assessing Arthrocentesis . . 112 Disclosure: Nothing to Disclose Joint Simulator. . . . . . . . . . . . . . . 67, 97 Disclosure: Nothing to Disclose Stevens, Anne M, MD, PhD Integrating Immunology and Biologics into Clinical Practice . . . . . . . . . . . . . . . . 25 Disclosure: Nothing to Disclose Kawasaki Disease in the 21st Century - Genes, Pathogenesis, and Biologics . . . . . . . . . 90 Disclosure: Nothing to Disclose Stone, John H, MD, MPH Session VI: Role of B cells in Autoimmunity: Lessons from Clinical Trials . . . . . . . . . . 23 Disclosure: Nothing to Disclose Curbside Consults - Ask the Professors . . . 62 Disclosure: Nothing to Disclose Treatment of Wegener’s Granulomatosis/ Microscopic Polyangiitis: Understanding and Applying the Data from Recent Clinical Trials . . . . . . . . . . . . . . . . . . . . . . . . . 48 Disclosure: Nothing to Disclose Suarez-Almazor, Maria E, MD, PhD Session I: The Essentials . . . . . . . . . . . 19 Disclosure: Nothing to Disclose Sukumaran, Sukesh, MBBS, MD Inflammatory Eye Disease . . . . . . . . . . 35 Disclosure: Nothing to Disclose Sulich, Andrew J, MD Hand X-ray Review and Interpretation. . . . 58 Disclosure: Nothing to Disclose Symmons, Deborah P, MD Economic Evaluations . . . . . . . . . . . . . 88 Disclosure: Nothing to Disclose Szekanecz, Zoltan, MD, PhD, DSC A Critical Role for Lipid Metabolism in the Interplay between Atherosclerosis and Autoimmune Disorders . . . . . . . . . . . .121 Disclosure: Nothing to Disclose Szer, Ilona S, MD Pediatric Systemic Lupus . . . . . . . . . . . 52 Disclosure: Nothing to Disclose T Tabechian, Darren, MD Musculoskeletal Ultrasound Course for Rheumatologists - Day One. . . . . . . . . . 18 Disclosure: Nothing to Disclose Musculoskeletal Ultrasound Course for Rheumatologists - Day Two . . . . . . . . . 22 Disclosure: Nothing to Disclose Tak, Paul P, MD, PhD The Preclinical Stage of Rheumatoid Arthritis: Towards Prevention of Disease? . . . . . . . 76 Disclosure: Roche/Genentech, 2, 5 Toll-like Receptors and Inflammation: Towards Innovative Treatment of Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . 38 Disclosure: NovImmune, 5 Takayanagi, Hiroshi, MD, PhD REF Oscar S. Gluck, MD, Memorial Lectureship - Osteoimmunology: Crosstalk Between the Immune and Bone Systems: Biologic and Clinical Implications . . . . . . . . . . . . . . . . . . 28 Disclosure: Nothing to Disclose Tall, Alan, MD A Critical Role for Lipid Metabolism in the Interplay between Atherosclerosis and Autoimmune Disorders . . . . . . . . . . . 121 Disclosure: BI, 5; Merck, 5; Novartis, 5; Pfizer, 5; Roache, 5 Talley, Anne Camille, MBA The Changing Face of the Rheumatology Workforce: Gender Issues in the Workplace . . . . . . . . . . . . . . . . . . . . . . . . . 94 Disclosure: Merck Telerx Division, 3; Schering Plough, 5; Various Investments in Stock & bond funds, 1 Talmadge, W. Tracy, PhD Reproductive and Sexual Health Issues for Women with Rheumatic Disease. . . . . . . 54 Disclosure: Nothing to Disclose Tan, Filemon K, MD, PhD Immunopathogenesis of Systemic Sclerosis. . . . . . . . . . . . . . . . . . . . . . . . . . . .136 Disclosure: Nothing to Disclose Taylor, Mihaela, MD Musculoskeletal Ultrasound Course for Rheumatologists - Day One. . . . . . . . . . 18 Disclosure: Nothing to Disclose Musculoskeletal Ultrasound Course for Rheumatologists - Day Two. . . . . . . . . . 22 Disclosure: Nothing to Disclose Tedder, Thomas, PhD Mouse to House: Lessons Learned About Lupus Therapeutics . . . . . . . . . . . . . . . . . . 39 Disclosure: Angelica Therapeutics, Inc., 1, 5 MedImmune, Inc., 5 Session IV: B Cell Regulation and B Cell Regulators . . . . . . . . . . . . . . . . . . . 23 Disclosure: Angelica Therapeutics, Inc., 1 MedImmune, Inc., 5
Terkeltaub, Robert, MD Crystallizing Your Assessment and Treatment of Difficult to Treat Gout . . . . . . . . . . . . .114 Disclosure: Amgen Veterinary, 5; Anadys, 5; ARDEA, 5; BioCryst, 5; Celgene, 5; Metabolex, 5; NIH, 2; Novartis, 5; Nuon, 5; Pfizer, 5; Prescription Solutions, 5; Regeneron, 5; Takeda, 9; UCB, 5; URL, 5; VA, 2 Tesser, John RP, MD Controversies in Osteoporosis and Low Bone Mass: Who Do We Treat, For How Long, and at What Risks? . . . . . . . . . . . . . . . . . .103 Disclosure: Nothing to Disclose Scleroderma: The Promise of Anti-fibrotic Therapies - A Translational Approach . . . . 67 Disclosure: Nothing to Disclose Theis, Kristina A, MPH Work Assessments: A ‘How-To’ That Could Save Your Patient’s Life/Job. . . . . . . . . . . . .131 Disclosure: Nothing to Disclose Thiele, Ralf G, MD Musculoskeletal Ultrasound Course for Rheumatologists - Day One. . . . . . . . . . 17 Disclosure: Abbott, 8; Amgen, 5; GE Healthcare, 9; Novartis, 5; Pfizer, 8; Sonosite, 9; UCB, 5 MSUS - Musculoskeletal Ultrasound Course for Rheumatologists - Day Two. . . . . . . . . . 22 Disclosure: Abbott, 8; Amgen, 5; GE Healthcare, 9; Novartis, 5; Pfizer, 8; Sonosite, 9; UCB, 5 Psoriatic Arthritis and Periarticular Imaging: Focus on Enthesitis, Dactylitis, and Nail Disease . . . . . . . . . . . . . . . . . . . . . 92 Disclosure: Abbott, 8; Amgen, 5; GE Healthcare, 9; Novartis, 5; Pfizer, 8; Sonosite, 9; UCB, 5 Thombs, Brett D, BA, MA, PhD Measure by Measure: Assessing Psychological Health and Well-Being in Scleroderma . . .135 Disclosure: Nothing to Disclose Thomson, Angus W, PhD Tolerogenic Dendritic Cells: Regulators of Immune Reactivity and Therapeutic Agents in Autoimmune Disease . . . . . . . . . . . . 101 Disclosure: Nothing to Disclose Tietge, Uwe J. F, MD A Critical Role for Lipid Metabolism in the Interplay between Atherosclerosis and Autoimmune Disorders . . . . . . . . . . . .121 Disclosure: Nothing to Disclose Tillman, Melesia Certified Rheumatology Coder Course . . . 20 Disclosure: Nothing to Disclose Ting, Tracy V, MD Juvenile Fibromyalgia . . . . . . . . . . . . . 53 Disclosure: Nothing to Disclose Torgerson, Troy R, MD, PhD Integrating Immunology and Biologics into Clinical Practice . . . . . . . . . . . . . . . . 25 Disclosure: Nothing to Disclose Trizuto, Jennifer L, MPT Total Shoulder Arthroplasty and Reverse Total Shoulder Arthroplasty: Surgery and Rehabilitation . . . . . . . . . . . . . . . . .147 Disclosure: Nothing to Disclose Troum, Orrin M, MD Peripheral Magnetic Resonance Imaging in Clinical Rheumatology . . . . . . . . . . 38, 62 Disclosure: International Society of Extremity MRI in Rheumatology, 6; Intersocietal Commission for the Accrediation of MRI Laboratories, 6 Troxell, Megan, MD Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis . . . . . . 33, 47 Disclosure: Nothing to Disclose Tse, Shirley, MD Pediatric Spondylarthropathies: From Genetics to the Clinic . . . . . . . . . . . . . . . . . .136 Disclosure: Abbott, 5; Merck/Schering Plough, 5; Wyeth, 5 Pediatrics: Spondyloarthritis in Children . . 96 Disclosure: Abbott, 5; Merck/Schering Plough, 5; Wyeth, 5 Tuan, Rocky S., PhD Stem Cell Reprogramming: Molecular Mechanisms and Clinical Applications and Implications . . . . . . . . . . . . . . . . . .102 Disclosure: Nothing to Disclose Tyndall, Alan G, MD Systemic Sclerosis: New Therapeutic Approaches . . . . . . . . . . . . . . . . . .122 Disclosure: Nothing to Disclose Scleroderma Mimics . . . . . . . . . . . . . 65 Disclosure: Nothing to Disclose U Uknis, Audrey B, MD ACR Leadership Town Hall Meeting . . . . .106 Disclosure: Nothing to Disclose V Valeriano-Marcet, Joanne, MD Rheumatic Manifestations of Neoplastic Diseases . . . . . . . . . . . . . . . . . . . . 24 Disclosure: Nothing to Disclose Teaching and Assessing Arthrocentesis . . 112 Disclosure: Nothing to Disclose Joint Simulator. . . . . . . . . . . . . . . 67, 97 Disclosure: Nothing to Disclose van de Laar, Mart A, MD Successful Coping with Rheumatic Disease 135 Disclosure: Nothing to Disclose Economic Evaluations . . . . . . . . . . . . . 88 Disclosure: Nothing to Disclose Van den Bosch, Filip E, MD, PhD Bowel Associated Rheumatologic Diseases . 24 Disclosure: Nothing to Disclose Van Der Heijde, Desiree M, MD, PhD Ankylosing Spondylitis: 2010 Update . 36, 105 Disclosure: abbott, 5; amgen, 5; bristol meyers squibb, 5; centocor, 5; chugai, 5; msd, 5; novartis, 5; pfizer, 5; roche, 5; ucb, 5 Van Lent, Peter, MD Molecular Mechanisms of Inflammatory Signaling in Cartilage Destruction . . . . . . 27 Disclosure: Nothing to Disclose Varga, John, MD Scleroderma: The Promise of Anti-fibrotic Therapies - A Translational Approach . . . . 67 Disclosure: BMS, 2; novartis, 2 Villa-Forte, Alexandra, MD, MPH Heparin and Antiphospholipid Syndromeinduced Thrombocytopenia . . . . . . . . . 31 Disclosure: Nothing to Disclose Vasculitis Mimics . . . . . . . . . . . . . . . 57 Disclosure: Nothing to Disclose Villasenor Ovies, Pablo, MD Rheumatology Physical Examination of Lower Extremity and Lumbosacral Spine: Anatomical Correlates . . . . . . . . . . . . . . . . . . . 38 Disclosure: Nothing to Disclose Rheumatology Physical Examination of Upper Extremity and Cervical Spine: Anatomical Correlates . . . . . . . . . . . . . . . . . . . 97 Disclosure: Nothing to Disclose Vivino, Frederick B, MD Controversies in Sjogren’s Syndrome . . 28, 83 Disclosure: Nothing to Disclose Vogler, Larry B, MD Pediatric Spondylarthropathies: From Genetics to the Clinic . . . . . . . . . . . . . . . . . .136 Disclosure: Nothing to Disclose Von Feldt, Joan Marie, MD, MS Ed Diagnostic Errors in Rheumatology: Why They Happen and How We Can Avoid Them . . . 67 Disclosure: Nothing to Disclose W Wallace, Carol A, MD Remission in Rheumatoid Arthritis. . . . . .137 Disclosure: Nothing to Disclose Ward, Michael M, MD Finding and Using Secondary Data Resources for Research: Beyond the National Health and Nutrition Examination Survey and the Usual Suspects . . . . . . . . . . . . . . . . . . . 103 Disclosure: Nothing to Disclose Ware, John, PhD Session I: The Essentials . . . . . . . . . . . 19 Disclosure: Nothing to Disclose Wasko, Mary Chester ACR/ABIM Maintenance of Certification Learning Session -2010 Update . . . . . . . 21 Disclosure: Nothing to Disclose Watcher, Sandra J, BSN Inflammatory Eye Disease . . . . . . . . . . 35 Disclosure: Nothing to Disclose Teaching Our Pediatric Patients: Making the Complex Simple . . . . . . . . . . . . . . . 142 Disclosure: Nothing to Disclose Integrating Immunology and Biologics into Clinical Practice . . . . . . . . . . . . . . . . 25 Disclosure: Nothing to Disclose INVITED SPEAKER /MODERATOR INDEX 2010 Program Book 313
Page 1 and 2:
program B O O K Pre-Conference Cour
Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
Page 11 and 12:
the written consent of the ACR is p
Page 13 and 14:
Shuttle Bus Service See shuttle sig
Page 15 and 16:
ACR Resource Center Hours: Sunday,
Page 17 and 18:
ACR Hotels + Map Complimentary shut
Page 19 and 20:
to the premier meeting in rheumatol
Page 21 and 22:
ACR Clinical Research Conference c/
Page 23 and 24:
4:20 PM Germinal Center Reactions A
Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
Page 27 and 28:
Upon completion of this session, pa
Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
Page 31 and 32:
B301 Dermatological Manifestations
Page 33 and 34:
Session Overview: The innate immune
Page 35 and 36:
Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
Page 39 and 40:
and insufficiency • recall source
Page 41 and 42:
Session Overview: The advent of bio
Page 43 and 44:
2:45 pm 641. Major Improvements in
Page 45 and 46:
5 University of Twente and Medisch
Page 47 and 48:
ACR/ARHP Combined Abstract Session
Page 49 and 50:
REF 25th Anniversary Celebration 2:
Page 51 and 52:
5:45 PM 699. Defining Latent and/or
Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
Page 59 and 60:
• discuss the principles of early
Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
Page 65 and 66:
ACR Plenary Session II: Discovery 2
Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
Page 69 and 70:
Session Overview: As a clinical edu
Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
Page 77 and 78:
2:45 PM 1405. Development of a Visi
Page 79 and 80:
4:30 PM Anti-citrullinated Protein
Page 81 and 82:
of Experimental Orthopedics, Univer
Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
Page 91 and 92:
• compare the prevalence and epid
Page 93 and 94:
6:45 PM Macrophage Activation Syndr
Page 95 and 96:
Page 97 and 98:
Session Overview: This roundtable d
Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
Page 103 and 104:
• describe the role of IL-1 and I
Page 105 and 106:
Session Overview: For the clinician
Page 107 and 108:
• identify the aspects for day-to
Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
Page 111 and 112:
Session Overview: Ultrasound and ma
Page 113 and 114:
Session Overview: Fifty percent of
Page 115 and 116:
1:20 PM Academic Rheumatology Seth
Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
Page 123 and 124:
Session Overview: We are witnessing
Page 125 and 126:
Session Overview: Systemic sclerosi
Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
Page 131 and 132:
4:30 PM 2198. Association between V
Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
Page 137 and 138:
• apply these basic statistics to
Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
Page 141 and 142:
Immunology, Oslo University Hospita
Page 143 and 144:
9:15 AM 2239. Factors Associated wi
Page 145 and 146:
Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
Page 151 and 152:
ACR Poster Session A Cytokines, Med
Page 153 and 154:
ACR Poster Session A 51. Associatio
Page 155 and 156:
ACR Poster Session A 83. Respirator
Page 157 and 158:
ACR Poster Session A 121. Bone Dens
Page 159 and 160:
ACR Poster Session A 142. The Intra
Page 161 and 162:
ACR Poster Session A 171. Early Pro
Page 163 and 164:
ACR Poster Session A Pediatric Rheu
Page 165 and 166:
ACR Poster Session A 233. Prevalenc
Page 167 and 168:
ACR Poster Session A 266. Subtype S
Page 169 and 170:
ACR Poster Session A 297. Body Weig
Page 171 and 172:
ACR Poster Session A 325. Patient R
Page 173 and 174:
ACR Poster Session A 356. Influence
Page 175 and 176:
ACR Poster Session A 383. Efficacy
Page 177 and 178:
ACR Poster Session A 409. Rituximab
Page 179 and 180:
ACR Poster Session A 441. Recombina
Page 181 and 182:
ACR Poster Session A 465. Immunoglo
Page 183 and 184:
ACR Poster Session A 496. IRF8 Alle
Page 185 and 186:
ACR Poster Session A 521. DC-STAMP
Page 187 and 188:
ACR Poster Session A 546. Prevalenc
Page 189 and 190:
ACR Poster Session A 571. Epidemiol
Page 191 and 192:
ACR Poster Session A 599. Validatio
Page 193 and 194:
ACR/ARHP Poster Session B Halls B1
Page 195 and 196:
ACR Poster Session B 767. Economic
Page 197 and 198:
ACR/ARHP Poster Session B 792. The
Page 199 and 200:
ACR/ARHP Poster Session B Universit
Page 201 and 202:
ACR/ARHP Poster Session B 848. Cell
Page 203 and 204:
ACR/ARHP Poster Session B 886. Scre
Page 205 and 206:
ACR/ARHP Poster Session B 909. Regu
Page 207 and 208:
ACR/ARHP Poster Session B 935. The
Page 209 and 210:
ACR/ARHP Poster Session B 967. Frac
Page 211 and 212:
ACR Poster Session B 993. Early Exp
Page 213 and 214:
ACR/ARHP Poster Session B 1022. Com
Page 215 and 216:
ACR/ARHP Poster Session B 1055. Son
Page 217 and 218:
ACR Poster Session B 1084. Gene Exp
Page 219 and 220:
ACR/ARHP Poster Session B 1111. Inc
Page 221 and 222:
ACR Poster Session B hiroshima Memo
Page 223 and 224:
ACR/ARHP Poster Session B 1166. Pre
Page 225 and 226:
ACR/ARHP Poster Session B 1199. Typ
Page 227 and 228:
ACR/ARHP Poster Session B 1225. Phy
Page 229 and 230:
ACR/ARHP Poster Session B 1262. Lat
Page 231 and 232:
ACR/ARHP Poster Session B 1294. End
Page 233 and 234:
ACR/ARHP Poster Session B 1321. Cha
Page 235 and 236:
ACR/ARHP Poster Session C Halls B1
Page 237 and 238:
ACR/ARHP Poster Session C 1495. S10
Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
Page 261 and 262:
ACR/ARHP Poster Session C 1804. Eff
Page 263 and 264: ACR/ARHP Poster Session C Immunolog
Page 265 and 266: ACR/ARHP Poster Session C 2 Departm
Page 267 and 268: ACR/ARHP Poster Session C CA, 29 Un
Page 269 and 270: ACR/ARHP Poster Session C 1900. IL-
Page 271 and 272: ACR/ARHP Poster Session C 1930. Cor
Page 273 and 274: ACR/ARHP Poster Session C 1958. The
Page 275 and 276: ACR/ARHP Poster Session C 1988. Cha
Page 277 and 278: ACR/ARHP Poster Session C 2015. CpG
Page 279 and 280: ACR/ARHP Poster Session C 2038. Pri
Page 281 and 282: ACR/ARHP Poster Session C 2070. Ass
Page 283 and 284: REF Industry Roundtable-supported S
Page 285 and 286: REF Industry Roundtable-supported S
Page 287 and 288: INDUSTRY-SUPPORTED POST-CONFERENCE
Page 289 and 290: 2010 ACR/ARHP Annual Meeting Leader
Page 291 and 292: 2010 ACR/ARHP Annual Meeting Leader
Page 293 and 294: FLOOR PLANS 2010 Program Book 291
Page 295 and 296: VISIT THE EXHIBIT HALL New and inno
Page 297 and 298: EXHIBITORS La Lettre Du Rhumatologu
Page 299 and 300: ACKNOWLEDGEMENTS The ACR, the ARHP
Page 301 and 302: ACR/ARHP/REF STAFF LISTING Administ
Page 303 and 304: A Ahmed, Rafi, PhD T cell Memory .
Page 305 and 306: Cooper, Max D, MD Introduction . .
Page 307 and 308: Gerlag, Danielle Marie, MD, PhD The
Page 309 and 310: Physical Examination Skills for Imp
Page 311 and 312: Meroni, Pierluigi, MD Autoantibodie
Page 313: Rogers, Joan C, PhD, OTR/ L Underst
Page 317 and 318: A Aarden, L 1825 Aarrass, S 1519, 1
Page 319 and 320: Bakker, AAB 1095 Barendregt, B 753
Page 321 and 322: Boutin-Le Thi Huong, D 478 Bout-Tab
Page 323 and 324: Chatham, WW 457, 1146, 1454, 1457,
Page 325 and 326: Daudon, M 875 Daugas, E 2009 Davatc
Page 327 and 328: Ehst, B 758 Eicher, JL 688 Eisen, S
Page 329 and 330: Gabay, OH 1484 Gaber, T 630, 1418 G
Page 331 and 332: Guan, M 965 Guañabens, N 975 Gudbj
Page 333 and 334: Homme, CL 730 Honda, E 434 Hong, JY
Page 335 and 336: Kambayashi, T 1354 Kamdar, AA 1160
Page 337 and 338: Kuller, LH 71 Kumabe, M 1164 Kumaga
Page 339 and 340: Looney, C 941 Looney, MR 609 Looney
Page 341 and 342: McCarthy, GM 1109, 1306, 1426 McCau
Page 343 and 344: Myouzen, K 1577 Mysiw, WJ 2096 Mysl
Page 345 and 346: Pans, M 1834 Parra, ER 605, 887 Ped
Page 347 and 348: Radka, S 1174 Radner, H 296, 1745 R
Page 349 and 350: Sack, KE 1898 Sacli, SF 1312 Saddic
Page 351 and 352: 1463, 2071, 2140, 2141 Singh, K 212
Page 353 and 354: Takahata, M 1492 Takasaki, Y 1731 T
Page 355 and 356: 636 van Dongen, CJJ 90 Van Doornum,
Page 357 and 358: Witte, T 824, 1578, 1579, 2214 Witt
Page 359 and 360: A α-galactosylceramide 505 A2A kno
Page 361 and 362: Behcet’s syndrome 1284, 1288, 129
Page 363 and 364: cost-utility 759, 1539 couples 1324
Page 365 and 366:
fibroblast like synoviocyte 27 fibr
Page 367 and 368:
impact 1063, 1325 inactive disease
Page 369 and 370:
methylation 826, 1253, 1489 methylt
Page 371 and 372:
233, 234, 240, 243, 252, 262, 268,
Page 373 and 374:
1599, 1600, 1603, 1605, 1606, 1609,
Page 375 and 376:
1226, 1227, 1229, 1230, 1231, 1233,
Page 377 and 378:
Abelson, Abby Goulder, MD Education
Page 379 and 380:
Massarotti, Elena M, MD Systemic Lu
Page 381 and 382:
ACR Annual Meeting fellowS-in-train
Page 383 and 384:
NOTES 2010 Program Book 381
Page 385 and 386:
Enbrel ® (etanercept) Brief Summar
Page 387 and 388:
Prescription Enbrel ® (etanercept)
show all

B O O K - American College of Rheumatology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?